<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Early tests suggest that the COVID-19 antibody treatment developed by Regeneron Pharmaceuticals Inc. REGN, +1.72% loses effectiveness against the omicron variant of the coronavirus that causes COVID, but the full impact will only be known in the coming weeks after further testing, the company’s president and chief scientific officer George Yancopoulos told the Wall Street Journal on Tuesday. Evercore analysts had raised that issue in a note to clients on Friday.
...read full article on Market Watch
